Celgene's drug is not the first oral treatment in the field – Pfizer's Xeljanz (tofacitinib) was approved for the treatment of rheumatoid arthritis in 2012, but has struggled to gain market share.

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

which is set to continue thanks to myeloma blockbuster Revlimid and new psoriasis and psoriatic arthritis drug Otezla. Celgene has been one of the sector's most spectacular success stories of ...

Celgene's apremilast ... 68% of the $3.5 billion global psoriasis market is captured by biologic therapies; topical agents and conventional systemic drugs account for ∼25% and ∼7%, respectively.

In the plaque psoriasis arena, Sotyktu is facing off ... a report from Spherix Global Insights found that Amgen’s oral drug Otezla—which incidentally Amgen acquired from BMS subsidiary Celgene—“has ...

The primary aim of the study was to explore the differences in gene expression profiles comparing PsA patients without cutaneous psoriasis (PsA-only ... type of biological disease-modifying ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Medicare coverage for psoriasis drugs depends on the type of Medicare plan you have and the drug your doctor prescribes. But if your doctor considers a drug medically necessary, Medicare may cover it.